Artigo de periodico

Complement C3 vs C5 inhibition in severe COVID-19: early clinical findings reveal differential biological efficacy (2020)

• Authors:
  • Mastellos, Dimitrios C.
  • Silva, Bruno Garcia Peixoto Pires da
  • Fonseca, Benedito Antonio Lopes da
  • Fonseca, Natasha Peixoto
  • Martins, Maria Auxiliadora
  • Mastaglio, Sara
  • Ruggeri, Annalisa
  • Sironi, Marina
  • Radermacher, Peter
  • Chrysanthopoulou, Akrivi
  • Skendros, Panagiotis
  • Ritis, Konstantinos
  • Manfra, Ilenia
  • Iacobelli, Simona
  • Huber-Lang, Markus
  • Nilsson, Bo
  • Yancopoulou, Despina
  • Connolly, E. Sander - Columbia University (CU)
  • Garlanda, Cecilia
  • Ciceri, Fabio
  • Risitano, Antonio M.
  • Calado, Rodrigo Tocantins
  • Lambris, John D. - University of Pennsylvania (UP)
• USP affiliated authors: FONSECA, BENEDITO ANTONIO LOPES DA - FMRP ; MARTINS, MARIA AUXILIADORA - FMRP ; RODRIGUES, RODRIGO DO TOCANTINS CALADO DE SALOMA - FMRP ; SILVA, BRUNO GARCIA PEIXOTO PIRES DA - FMRP ; FONSECA, NATASHA PEIXOTO - FMRP
• Unidade: FMRP
• DOI: 10.1016/j.clim.2020.108598
• Subjects: COVID-19; TROMBOSE; FÁRMACOS; BIOMARCADORES
• Keywords: Thromboinflammation; C3 inhibition; C5 blockade; AMY-101; Eculizumab; Drug efficacy; Biomarkers
• Agências de fomento:
  • Financiado pela Alexion Pharmaceuticals
  • Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
    Processo FAPESP: 13/08135-2
• Language: Inglês
• Imprenta:
  • Publisher place: Maryland Heights
  • Date published: 2020
• Source:
  • Título do periódico: Clinical Immunology
  • ISSN: 1521-6616
  • Volume/Número/Paginação/Ano: v. 220, art. 108598, 2020

Informações sobre o DOI: 10.1016/j.clim.2020.108598 (Fonte: oaDOI API)
• Este periódico é de assinatura
• Este artigo é de acesso aberto
• URL de acesso aberto
• Cor do Acesso Aberto: green
• Licença: other-oa

---

Download do texto completo

Tipo	Nome	Link
	003029634.pdf

How to cite

A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

• ABNT

  MASTELLOS, Dimitrios C. et al. Complement C3 vs C5 inhibition in severe COVID-19: early clinical findings reveal differential biological efficacy. Clinical Immunology, v. 220, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.clim.2020.108598. Acesso em: 24 abr. 2024.

• APA

  Mastellos, D. C., Silva, B. G. P. P. da, Fonseca, B. A. L. da, Fonseca, N. P., Martins, M. A., Mastaglio, S., et al. (2020). Complement C3 vs C5 inhibition in severe COVID-19: early clinical findings reveal differential biological efficacy. Clinical Immunology, 220. doi:10.1016/j.clim.2020.108598

• NLM

  Mastellos DC, Silva BGPP da, Fonseca BAL da, Fonseca NP, Martins MA, Mastaglio S, Ruggeri A, Sironi M, Radermacher P, Chrysanthopoulou A, Skendros P, Ritis K, Manfra I, Iacobelli S, Huber-Lang M, Nilsson B, Yancopoulou D, Connolly ES, Garlanda C, Ciceri F, Risitano AM, Calado RT, Lambris JD. Complement C3 vs C5 inhibition in severe COVID-19: early clinical findings reveal differential biological efficacy [Internet]. Clinical Immunology. 2020 ; 220[citado 2024 abr. 24 ] Available from: https://doi.org/10.1016/j.clim.2020.108598

• Vancouver

  Mastellos DC, Silva BGPP da, Fonseca BAL da, Fonseca NP, Martins MA, Mastaglio S, Ruggeri A, Sironi M, Radermacher P, Chrysanthopoulou A, Skendros P, Ritis K, Manfra I, Iacobelli S, Huber-Lang M, Nilsson B, Yancopoulou D, Connolly ES, Garlanda C, Ciceri F, Risitano AM, Calado RT, Lambris JD. Complement C3 vs C5 inhibition in severe COVID-19: early clinical findings reveal differential biological efficacy [Internet]. Clinical Immunology. 2020 ; 220[citado 2024 abr. 24 ] Available from: https://doi.org/10.1016/j.clim.2020.108598

Últimas obras dos mesmos autores vinculados com a USP cadastradas na BDPI:

• Aplicabilidade da calorimetria indireta na medida do débito cardíaco em pacientes sépticos
• Patterns of intravenous fluid resuscitation use in adult intensive care patients between 2007 and 2014: An international cross-sectional study
• Fração de recuperação do 13CO2 no ar expirado de pacientes sépticos sob ventilação mecânica
• 17DD and 17D-213/77 yellow fever substrains trigger a balanced cytokine profile in primary vaccinated children
• Targeting complement to treat paroxysmal nocturnal hemoglobinuria (PNH)
• Telomere dynamics in mice and humans
• A mutation in the H/ACA box of telomerase RNA component gene (TERC) in a young patient with myelodysplastic syndrome
• Repeat course of rabbit antithymocyte globulin as salvage following initial therapy with rabbit antithymocyte globulin in acquired aplastic anemia
• Repeat course of rabbit antithymocyte globulin as salvage following initial therapy with rabbit antithymocyte globulin in acquired aplastic anemia. [Carta]
• Latin American Collaborative Research on Aplastic Anemia (LARAA): creating a regional registry